{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:52:44Z","timestamp":1790401964934,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["565074"],"award-info":[{"award-number":["565074"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.expneurol.2014.09.008","type":"journal-article","created":{"date-parts":[[2014,9,21]],"date-time":"2014-09-21T21:03:14Z","timestamp":1411333394000},"page":"79-90","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"special_numbering":"C","title":["Delivery of therapeutic protein for prevention of neurodegenerative changes: Comparison of different CSF-delivery methods"],"prefix":"10.1016","volume":"263","author":[{"given":"Neil R.","family":"Marshall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Hassiotis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Rozaklis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Trim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen K.","family":"Duplock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne K.","family":"Winner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Beard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marten F.","family":"Snel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Jolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Hopwood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim M.","family":"Hemsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2014.09.008_bb0005","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ymgme.2009.10.002","article-title":"Repeated intrathecal injections of recombinant human 4-sulphatase remove dural storage in mature mucopolysaccharidosis VI cats primed with a short-course tolerisation regimen","volume":"99","author":"Auclair","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0010","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/pr.2011.13","article-title":"Intrathecal recombinant human 4-sulfatase reduces accumulation of glycosaminoglycans in dura of mucopolysaccharidosis VI cats","volume":"71","author":"Auclair","year":"2012","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0015","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.cca.2012.01.012","article-title":"An improved method for glycosaminoglycan analysis by LC\u2013MS\/MS of urine samples collected on filter paper","volume":"413","author":"Auray-Blais","year":"2012","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.expneurol.2014.09.008_bb0020","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1093\/glycob\/9.12.1389","article-title":"A mouse model for mucopolysaccharidosis type III A (Sanfilippo syndrome)","volume":"9","author":"Bhaumik","year":"1999","journal-title":"Glycobiology"},{"key":"10.1016\/j.expneurol.2014.09.008_bb0025","doi-asserted-by":"crossref","first-page":"e30341","DOI":"10.1371\/journal.pone.0030341","article-title":"CNS penetration of intrathecal-lumbar idursulfase in the monkey, dog and mouse: implications for neurological outcomes of lysosomal storage disorder","volume":"7","author":"Calias","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.expneurol.2014.09.008_bb0030","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1055\/s-2008-1071387","article-title":"Sanfilippo A disease in the fetus\u2014comparison with pre- and postnatal cases","volume":"11","author":"Ceuterick","year":"1980","journal-title":"Neuropadiatrie"},{"key":"10.1016\/j.expneurol.2014.09.008_bb0035","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/mt.2008.9","article-title":"Intraventricular enzyme replacement improves disease phenotypes in a mouse model of late infantile neuronal ceroid lipofuscinosis","volume":"16","author":"Chang","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2006.05.079","article-title":"Characterization of a C57BL\/6 congenic mouse strain of mucopolysaccharidosis type IIIA","volume":"1104","author":"Crawley","year":"2006","journal-title":"Brain Res."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0045","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.nbd.2011.04.014","article-title":"Enzyme replacement reduces neuropathology in MPS IIIA dogs","volume":"43","author":"Crawley","year":"2011","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0050","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ymgme.2006.12.012","article-title":"Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid","volume":"91","author":"Dickson","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0055","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ymgme.2010.06.020","article-title":"Early versus late treatment of spinal cord compression with long-term intrathecal enzyme replacement therapy in canine mucopolysaccharidosis type I","volume":"101","author":"Dickson","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0060","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.ymgme.2012.02.003","article-title":"Specific antibody titer alters the effectiveness of intrathecal enzyme replacement therapy in canine mucopolysaccharidosis I","volume":"106","author":"Dickson","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0065","doi-asserted-by":"crossref","first-page":"946","DOI":"10.2174\/138920111795542642","article-title":"Intrathecal enzyme replacement therapy for mucopolysaccharidosis I: translating success in animal models to patients","volume":"12","author":"Dickson","year":"2011","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0070","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.expneurol.2008.10.021","article-title":"Intracerebroventricular infusion of acid sphingomyelinase corrects CNS manifestations in a mouse model of Niemann\u2013Pick A disease","volume":"215","author":"Dodge","year":"2009","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0075","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0021-9258(18)64849-5","article-title":"A simple method for the isolation and purification of total lipids from animal tissues","volume":"226","author":"Folch","year":"1957","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0080","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1093\/hmg\/ddm223","article-title":"Functional correction of CNS lesions in a MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes","volume":"16","author":"Fraldi","year":"2007","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0085","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1203\/01.PDR.0000129661.40499.12","article-title":"Enzyme-replacement therapy from birth delays the development of behavior and learning problems in mucopolysaccharidosis type IIIA mice","volume":"56","author":"Gliddon","year":"2004","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0090","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1111\/ejn.12557","article-title":"Disease stage determines the efficacy of treatment of a paediatric neurodegenerative disease","volume":"39","author":"Hassiotis","year":"2014","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0095","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ymgme.2006.10.005","article-title":"Injection of recombinant human sulfamidase into the CSF via the cerebellomedullary cistern in MPS IIIA mice","volume":"90","author":"Hemsley","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0100","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1111\/j.1601-183X.2008.00413.x","article-title":"Effect of high dose, repeated intra-CSF injection of sulphamidase on neuropathology in MPS IIIA mice","volume":"7","author":"Hemsley","year":"2008","journal-title":"Genes Brain Behav."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0105","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1111\/j.1460-9568.2009.06666.x","article-title":"Examination of intravenous and intra-CSF protein delivery for treatment of neurological disease","volume":"29","author":"Hemsley","year":"2009","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0110","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ymgme.2009.07.013","article-title":"Effect of cisternal sulfamidase delivery in MPS IIIA Huntaway dogs\u2014a proof of principle study","volume":"98","author":"Hemsley","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0115","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0009-8981(82)90168-1","article-title":"Diagnosis of Sanfilippo type A syndrome by estimation of sulfamidase activity using a radiolabelled tetrasaccharide substrate","volume":"123","author":"Hopwood","year":"1982","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.expneurol.2014.09.008_bb0120","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1194\/jlr.D800038-JLR200","article-title":"Targeted analysis of ganglioside and sulphatide molecular species by LC\/ESI\u2013MS\/MS with theoretically expanded multiple reaction monitoring","volume":"49","author":"Ikeda","year":"2008","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0125","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1080\/00480169.2000.36181","article-title":"Mucopolysaccharidosis IIIA (Sanfilippo syndrome) in a New Zealand Huntaway dog with ataxia","volume":"48","author":"Jolly","year":"2000","journal-title":"N. Z. Vet. J."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0130","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/j.1365-2990.2010.01158.x","article-title":"Intracisternal enzyme replacement therapy in lysosomal storage diseases: routes of absorption into brain","volume":"37","author":"Jolly","year":"2011","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0135","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/nan.12010","article-title":"Intracisternal enzyme replacement therapy in lysosomal storage diseases: dispersal pathways, regional enzyme concentrations and the effect of post-treatment posture","volume":"39","author":"Jolly","year":"2013","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0140","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2004.07.003","article-title":"Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I","volume":"83","author":"Kakkis","year":"2004","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0145","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s004010050796","article-title":"Lectin histochemistry in the aged dog brain","volume":"95","author":"Kiatipattanasakul","year":"1998","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0150","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.expneurol.2011.04.019","article-title":"Treatment of canine fucosidosis by intracisternal enzyme infusion","volume":"230","author":"Kondagari","year":"2011","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0155","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.ymgme.2003.11.007","article-title":"In vitro characterization of genetically modified embryonic stem cells as a therapy for murine mucopolysaccharidosis type IIIA","volume":"81","author":"Lau","year":"2004","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0160","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ymgme.2010.02.006","article-title":"SGSH gene transfer in mucopolysaccharidosis type IIIA mice using canine adenovirus vectors","volume":"100","author":"Lau","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0165","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.expneurol.2010.07.024","article-title":"Allogeneic stem cell transplantation does not improve neurological deficits in mucopolysaccharidosis type IIIA mice","volume":"225","author":"Lau","year":"2010","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0170","doi-asserted-by":"crossref","first-page":"2520","DOI":"10.1096\/fj.06-6169com","article-title":"Single-dose intracerebroventricular administration of galactocerebrosidase improves survival in a mouse model of globoid cell leukodystrophy","volume":"21","author":"Lee","year":"2007","journal-title":"FASEB J."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0175","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ymgme.2009.06.013","article-title":"Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharide IIIB mice","volume":"98","author":"Malinowska","year":"2009","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0180","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/mt.2011.27","article-title":"Therapeutic potential of intracerebroventricular replacement of modified human beta-hexosaminidase B for GM2 gangliosidosis","volume":"19","author":"Matsuoka","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0185","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/cne.20355","article-title":"Differential subcellular localization of cholesterol, gangliosides, and glycosaminoglycans in murine models of mucopolysaccharide storage disorders","volume":"480","author":"McGlynn","year":"2004","journal-title":"J. Comp. Neurol."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0190","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","article-title":"Prevalence of lysosomal storage disorders","volume":"281","author":"Meikle","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.expneurol.2014.09.008_bb0195","series-title":"The Metabolic and Molecular Bases of Inherited Diseases","first-page":"3421","article-title":"The mucopolysaccharidoses","author":"Neufeld","year":"2001"},{"key":"10.1016\/j.expneurol.2014.09.008_bb0200","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ymgme.2007.06.016","article-title":"Improvement in behaviour after substrate deprivation therapy with rhodamine B in a mouse model of MPS IIIA","volume":"92","author":"Roberts","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0205","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.expneurol.2011.04.004","article-title":"Impact of high-dose, chemically modified sulfamidase on pathology in a murine model of MPS IIIA","volume":"230","author":"Rozaklis","year":"2011","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0210","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1089\/hum.2012.029","article-title":"Correction of pathological accumulation of glycosaminoglycans in central nervous system and peripheral tissues of MPS IIIA mice through systemic AAV9 gene transfer","volume":"23","author":"Ruzo","year":"2012","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0215","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/ng1295-465","article-title":"Cloning of the sulphamidase gene and identification of mutations in Sanfilippo A syndrome","volume":"11","author":"Scott","year":"1995","journal-title":"Nat. Genet."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0220","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/emmm.201202083","article-title":"A highly secreted sulphamidase engineered to cross the blood\u2013brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIA","volume":"5","author":"Sorrentino","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0225","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1093\/hmg\/ddr175","article-title":"Intracerebroventricular enzyme infusion corrects central nervous system pathology and dysfunction in a mouse model of metachromatic leukodystrophy","volume":"20","author":"Stroobants","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0230","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/rcm.6861","article-title":"A simple method for early age phenotype confirmation using toe tissue from a mouse model of MPS IIIA","volume":"28","author":"Trim","year":"2014","journal-title":"Rapid Commun. Mass Spectrom."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0235","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ana.22262","article-title":"Highly phosphomannosylated enzyme replacement therapy for GM2 gangliosidosis","volume":"69","author":"Tsuji","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0240","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1002\/ana.22092","article-title":"Mucopolysaccharidosis type IIIA: clinical spectrum and genotype-phenotype correlations","volume":"68","author":"Valstar","year":"2010","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0245","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.ymgme.2011.03.011","article-title":"Biodistribution and pharmacodynamics of recombinant human alpha-L-iduronidase (rhIDU) in mucopolysaccharidosis type I-affected cats following multiple intrathecal administrations","volume":"103","author":"Vite","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0250","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3109\/08941939809098035","article-title":"Method for long-term cerebrospinal fluid collection in the conscious dog","volume":"11","author":"Wilsson-Rahmberg","year":"1998","journal-title":"J. Investig. Surg."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0255","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.expneurol.2007.06.017","article-title":"Intraparenchymal injections of acid sphingomyelinase results in regional correction of lysosomal storage pathology in the Niemann\u2013Pick A mouse","volume":"207","author":"Yang","year":"2007","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2014.09.008_bb0260","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1006\/geno.2002.6699","article-title":"Identification of a mutation causing mucopolysaccharidosis type IIIA in New Zealand Huntaway dogs","volume":"79","author":"Yogalingam","year":"2002","journal-title":"Genomics"}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448861400291X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448861400291X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T10:16:26Z","timestamp":1772100986000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001448861400291X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":52,"alternative-id":["S001448861400291X"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2014.09.008","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Delivery of therapeutic protein for prevention of neurodegenerative changes: Comparison of different CSF-delivery methods","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2014.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}